Document is current
Any future updates will be listed below
-
Authors
Samra, Bachar
Jabbour, Elias
Ravandi, Farhad
Kantarjian, Hagop
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
- License Information
-
More Information
Article History
Received: 20 April 2020
Accepted: 22 May 2020
First Online: 5 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: E. Jabbour has research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. F. Ravandi has had honoraria and has been a member advisory board with BMS, Novartis, AbbVie, and Amgen. H. Kantarjian reports grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. N.J. Short has served as a consultant for Takeda Oncology and AstraZeneca, reports receiving commercial research grants from Takeda Oncology and Astellas Pharma Inc., and has received speakers’ bureau honoraria from Amgen.
